Burlingame, CA, United States of America

Sushant Malhotra

This inventor holds 21 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Genentech, Inc., Eli Lilly and Company, Green Tech Corporation. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sushant Malhotra. Retrieved from https://idiyas.com/inventor/sushant-malhotra

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 12)

% Patents Active = 71.4

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 16)

Average Co-Inventor Count = 9.0

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

Los Altos, CA (US) (2009)
Indianapolis, IN (US) (2006 - 2011)
Burlingame, CA (US) (2011 - 2024)
South San Francisco, CA (US) (2019 - 2024)

Company Filing History:

Eli Lilly and Company

patents

1 out of 8

Green Tech Corporation

patents

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

Isoquinoline Compounds

Naphthyridine Compounds

Spirocyclic Compounds

Fused Ring Compounds

Azaindoles

BTK Inhibitors

Purine Derivatives

TGF-β Inhibitors

Pharmaceutical Agents

GSK-3 Inhibitors

Proliferative Diseases

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

2. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

3. 12208088 - Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof (2025-01-28),

4. 12084429 - Fused ring compounds (2024-09-10),

5. 11944606 - Azaindoles as inhibitors of HPK1 (2024-04-02),

6. 11760744 - Fused ring compounds (2023-09-19),

7. 11661424 - Process for preparing BTK inhibitors (2023-05-30),

8. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

9. 11236068 - Fused ring compounds (2022-02-01),

10. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

11. 10952995 - Azaindoles as inhibitors of HPK1 (2021-03-23),

12. 10882864 - Process for preparing BTK inhibitors (2021-01-05),

13. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),

14. 10385058 - Process for preparing BTK inhibitors (2019-08-20),

15. 9303043 - Process for making benzoxazepin compounds (2016-04-05),

Title: Unveiling the Innovations of Sushant Malhotra: Pioneer in Biomedical Research

Introduction

Sushant Malhotra, a distinguished inventor based in Burlingame, CA (US), has made significant contributions to the field of biomedical research, holding an impressive 17 patents. His cutting-edge inventions have revolutionized the treatment of HPK1-dependent disorders and enhanced immune responses. Let's delve into the remarkable achievements of this visionary inventor.

Latest Patents

Malhotra's latest patents showcase his expertise in developing groundbreaking solutions for inhibiting HPK1 and Ras proteins. One of his pioneering patents involves the use of Azaindole compounds as inhibitors of HPK1, providing novel methods for treating HPK1-dependent disorders and boosting immune responses. Additionally, his invention of fused ring compounds has paved the way for innovative treatments targeting Ras proteins, offering new possibilities in medical intervention.

Career Highlights

Throughout his career, Sushant Malhotra has lent his inventive prowess to renowned companies such as Genentech, Inc. and Eli Lilly and Company. His tenure at these esteemed organizations has been marked by a relentless pursuit of innovation, leading to the creation of cutting-edge solutions that have the potential to transform healthcare practices worldwide.

Collaborations

Malhotra's collaborative endeavors with esteemed colleagues such as Thomas Albert Engler and BinQing Wei have further enriched the landscape of biomedical research. Together, they have synergized their expertise to propel forward groundbreaking projects, fostering a culture of innovation and excellence in their respective fields.

Conclusion

In conclusion, Sushant Malhotra stands as a beacon of innovation in the realm of biomedical research, with a rich tapestry of patents that embody his relentless pursuit of excellence. His unwavering dedication to developing novel solutions for healthcare challenges underscores his status as a trailblazer in the field. Malhotra's work continues to inspire and drive advancements in biomedical science, leaving an indelible mark on the landscape of innovation.

Profile summary based on public USPTO records.